Search clinical trials for: ZD1839

Total 96 results

AstraZeneca

Completed

IRESSA™ (Gefitinib) in Breast Cancer Patients

Breast Cancer
AstraZeneca

Completed

Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers

Healthy Volunteers | Alzheimer's Disease | Tolerability | Safety | Blood Concentration

United Kingdom
NSABP Foundation Inc
AstraZeneca

Completed

Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer

Breast Neoplasms

United States
SCRI Development Innovations, LLC
AstraZeneca

Completed

Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer

Lung Cancer
Galecto Biotech AB

Completed

RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients

Idiopathic Pulmonary Fibrosis

United Kingdom
AstraZeneca

Approved for marketing

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Non Small Cell Lung Cancer | Cancer of the Head and Neck

Poland, Germany, Hungary, United Kingdom
AstraZeneca

Completed

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Pulmonary Cancer

Korea, Republic of
University of Chicago

Completed

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

Head and Neck Cancer

United States
AstraZeneca

Withdrawn

Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (IMAC/Herbst)

Non-Small-Cell Lung Carcinoma
Indiana University School of Medicine
AstraZeneca

Terminated

A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR (IUCRO-0021)

Refractory Germ Cell Tumors Expressing EGRF

United States
AstraZeneca

Completed

An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma

Mesothelioma
AstraZeneca

Approved for marketing

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Non Small Cell Lung Cancer (NSCLC)

Taiwan, Thailand, Turkey, Brazil, Philippines, Russian Federation, Romania, Austria, Hungary, Bulgaria, Latvia, India, Argentina, Australia, Estonia, Malaysia, Mexico, Singapore, South Africa
AstraZeneca

Completed

Iressa Expanded Access Program (EAP)

Carcinoma | Neoplasm | Non-small-cell Lung | Metastases

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer

Esophageal Cancer

United States
AstraZeneca

Completed

Trial of Iressa in Prostate Cancer Patients

Prostate Cancer

Canada
University Hospital of Crete

Completed

A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer

Breast Cancer

Greece
Genzyme, a Sanofi Company

Completed

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

Carcinoma, Non-Small-Cell Lung

United States, South Africa, United Kingdom, Germany, Argentina, Belgium
Sidney Kimmel Cancer Center at Thomas Jefferson...
AstraZeneca

Completed

ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma (NSCLC)

United States
M.D. Anderson Cancer Center
AstraZeneca

Completed

Iressa Study in Patients With Salivary Gland Cancer

Salivary Gland Cancer

United States
M.D. Anderson Cancer Center
AstraZeneca

Completed

ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

Skin Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); AstraZeneca

Terminated

Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates

Lung Cancer

United States
AstraZeneca

Completed

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

Advanced Tumor

Netherlands
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery

Esophageal Cancer

United States
University of Chicago
National Cancer Institute (NCI)

Completed

ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck

Head and Neck Cancer

United States
Weill Medical College of Cornell University

Terminated

Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer

Head and Neck Cancer

United States
Massachusetts General Hospital
National Cancer Institute (NCI); Dana-Farber Cancer Institute; AstraZeneca; Brigham...

Completed

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Head and Neck Cancer

United States
Betta Pharmaceuticals Co., Ltd.

Completed

Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients (ICOGEN)

Non-small Cell Lung Cancer

China
Galecto Biotech AB
Syneos Health; bioRASI, LLC

Completed

A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis (IPF)

United States, Spain, Israel, France, United Kingdom, Australia, Italy, Germany, Canada, Belgium, Georgia, Ireland, Poland, Ukraine
Hutchison Medipharma Limited
AstraZeneca

Completed

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Non-Small Cell Lung Cancer

China
Dartmouth-Hitchcock Medical Center
M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; AstraZeneca; Kentuckiana...

Completed

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Nonresectable Adrenocortical Carcinoma

United States
AstraZeneca

Completed

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

Neoplasms, Squamous Cell

United States, Czech Republic, Poland, Germany, Belgium, Taiwan, India, Serbia
3D Medicines

Active, not recruiting

Study of 3D189 in Patients With Hematologic Malignancies

Multiple Myeloma | Non-Hodgkin Lymphoma | Acute Leukemia | Higher-risk Myelodysplastic Syndrome

China
Benaroya Research Institute
Sanofi; AstraZeneca

Completed

Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer

Prostate Cancer

United States
AstraZeneca

Completed

Iressa as Second Line Therapy in Advanced NSCLC-Asia (ISTANA)

NSCLC

Korea, Republic of
Ophthalmic Consultants of Long Island
Pfizer

Completed

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

Dry Eye Disease

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

Colorectal Cancer

United States
M.D. Anderson Cancer Center
AstraZeneca; Aventis Pharmaceuticals

Withdrawn

Iressa/Docetaxel in Non-Small-Cell Lung Cancer

Non-small Cell Lung Cancer

United States
AstraZeneca

Completed

ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer

Head and Neck Cancer

Spain
University of Nebraska
National Cancer Institute (NCI)

Terminated

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

Prostate Cancer

United States
David Adelstein
National Cancer Institute (NCI)

Completed

Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer

Head and Neck Cancer

United States
AstraZeneca

Completed

First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia (IPASS)

Non-Small Cell Lung Cancer

Philippines, China, Malaysia, Japan, Hong Kong, Taiwan, Thailand, Indonesia, Singapore
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Completed

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Baylor Breast Care Center
AstraZeneca

Terminated

Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients

Breast Cancer

United States
AstraZeneca

Completed

Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT

Bladder Cancer

Germany
AstraZeneca

Completed

Phase II Iressa & Carbo/Gem in NSCLC

Carcinoma, Non-Small-Cell Lung

Canada
Massachusetts General Hospital
Dana-Farber Cancer Institute; Brigham and Women's Hospital

Completed

Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer

Ovarian Cancer | Peritoneal Carcinoma | Tubal Carcinoma

United States
Guangdong Provincial People's Hospital

Unknown

PK/PD of the Sedatives, Analgesics and Antibiotics in Patients Receiving ECMO

Drug Effect

China
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Lung Cancer

United States
AGO Study Group

Completed

A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

Ovarian Cancer | Peritoneal Cancer | Cancer of the Fallopian Tube

Germany
National University Hospital, Singapore
National Healthcare Group, Singapore

Completed

A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839

Nasopharyngeal Carcinoma

Singapore

Search clinical trials for: ZD1839

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations